image

Authoritative Independent Monthly Share Selections Using Technical & Fundamental Analysis

Latest issue now available

SIGN UP NOW
Secondary Recommendation

Dechra Pharmaceuticals - Impending US drug approval could herald profit surge

April 2007

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • DPH
  • Price:
  • 293p
Most small drug development firms make very dangerous investments because they typically don’t have the profitable backbone to finance the long lead times required to get potential block-busters to market. In other words, it’s a case of shoot the lights out or go bust. However, Dechra Pharmaceuticals (FT sector: Pharmaceuticals & Biotech), which manufactures and sells pharmaceutical products mainly to the animal health market, has that nice balance between steady profits and raw excitement surrounding two of its proprietary drugs which will soon launch in the much bigger US market. The majority of Dechra’s business is generated by its Services division, NVS (64% profit), which apart from a small laboratories ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Related Articles

Dechra Pharmaceuticals (November 2010)
Dechra Pharmaceuticals - US launch of Vetoryl to boost profits (February 2010)
Dechra Pharmaceuticals (November 2008)
Dechra Pharmaceuticals - US blockbuster potential for key drug (August 2008)
Dechra Pharmaceuticals - Gains approach £1 per share (November 2005)
Dechra Pharmaceuticals (April 2005)
Dechra Pharmaceuticals - Positive AGM (December 2004)
Dechra Pharmaceuticals - New animal drug could be blockbuster (October 2004)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X